Abstract: The relation of Mycobacterium avium ss paratuberculosis (MAP) to Crohn's Disease (CD) and other MAP-associated conditions remains controversial. New data, coupled with the analogous Helicobacter pylori (H. pylori) story, has permitted us to piece together the MAP puzzle and move forward with a more scientific way of treating inflammatory bowel disease, particularly CD. As infection moves centre stage in inflammatory bowel disease, the dated "aberrant reaction" etiology has lost scientific credibility. Now, our growing understanding of MAP-associated diseases demands review and articulation. We focus here on (1) the concept of MAP-associated diseases; (2) causality, Johne Disease, the "aberrant reaction" hypothesis; and (3) responses to published misconceptions questioning MAP as a pathogen in CD.
PARADIGM SHIFT
Similar indoctrination to the "no acid no ulcer" H. pylori dictum 12 again prevents us from accepting an infectious CD etiology, and instead blindly accepting a nebulous, unproven "aberrant immune reaction theory." 13 Are we again "repeating the mistake of H. pylori?" 1 
VARIABLE DISEASE CHARACTERISTICS
Although it is plausible that several pathogens cause CD-like pathology, 11 Prantera 2 suggested "variable disease locations and severity" disprove a single pathogen etiology. Yet a number of pathogens cause "variable disease locations and severity." Tuberculosis (TB) is a classic example. Around 90% of patients with TB have latent infection. 14 In the remaining 10%, there can be lymph node TB, 15 miliary TB, 16 pulmonary TB, 17 central nervous system TB, 18 cervical TB, 19 adrenal TB, 20 or joint TB. 21 H. pylori, another versatile pathogen can cause an asymptomatic carrier state, mild nonulcer dyspepsia, duodenal or gastric ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric carcinoma. 6 Hence, variable presentations can be the result of a single pathogen. The reverse can also be true; with different etiologic agents causing similar presentations, for example. H. pylori, H. heilmanii, anti-inflammatory drugs, and pancreatic cancer can all cause "duodenal ulcers." 22 
KOCH'S POSTULATES AND CAUSALITY
Koch's Postulates, the gold standard for establishing microbial causality of disease, was first described by Robert Koch in 1884 when he established a bacterial cause of Mycobacterium tuberculosis (M. tuberculosis)-associated diseases. 23 The Postulates included the following.
1. Growing the bacteria from infected tissue in pure culture. 2. Introducing these bacteria into an animal model to reproduce the disease. 3. Recovering the same bacteria from the diseased animal model. In 1986, Van Kruiningen et al 24 isolated MAP in pure culture from a CD patient, infecting infant goats with this pathogen which resulted in humoral and cell-mediated responses at 3 weeks and terminal ileitis at 5 months. MAP was recovered thereby fulfilling Koch's Postulates. Fredricks and Relman (1996) updated these Postulates to incorporate molecular methods to deal with evolving infections, which have also been met for MAP in CD. 25, 26 It is vital to note that antibiotic trials play no part in establishing Koch's Postulates of causality.
Dr Steven Hanauer, an internationally recognized and respected inflammatory bowel disease (IBD) expert, agreed in his editorial that Koch's Postulates remain crucial in proving disease causality. 27 Prantera 2 also confirmed the Postulates had been fulfilled for MAP in CD. We now must question why "leaders in the field" are unwilling to accept evidence-based findings and continue to request treatment trials 28 
CURRENT IBD ETIOLOGY HYPOTHESIS
The dominant IBD hypothesis states that "dysregulation of the mucosal immune system in a genetically predisposed individual leads to an exaggerated and ongoing activation of immunologic responses to the person's own normal microflora." 13 Although genetic interactions play some predisposing role in CD causation as they do in TB, 32 the rapidly rising incidence of CD worldwide cannot be explained by genetic mutations. 33 Epidemiologic studies have shown substantial overlaps of CD in regions that have high levels of environmental MAP, with a recent Japanese study finding a statistical correlation between increased CD incidence and increasing consumption of animal proteins, particularly milk, a known source of viable MAP. 34 Another significant finding is that of isolated duodenal CD. 35, 36 An "aberrant response to normal colonic flora" simply cannot exist in the duodenum, an area devoid of colonic bacteria, and is enough alone to disprove the current hypothesis. If we are to advance our understanding of IBD causality, these glaring anomalies can no longer be ignored, suggesting a timely reexamination of the current IBD hypothesis with the same scrutiny afforded to MAP.
It is critical that we be cognizant of what we know and what we merely assume, of what we submit as a plausible hypothesis, and what has accumulated sufficient evidence to be regarded as substantive theory. The real danger lies in repeating plausible hypotheses long and often enough for the medical community to regard them as accepted theories. The longstanding acceptance of the CD "Autoimmune Hypothesis" speaks to this danger. Currently, the same danger exists for the unquestioned, accepted hypothesis that the commensal microbiota in genetically susceptible hosts is responsible for CD development-to the exclusion of specific bacterial infections in these same genetically predisposed individuals.
JD
JD, the animal equivalent of CD, is irrefutably caused by MAP. 37 As early as 1913, Dalziel, 38 a surgeon familiar with JD, observed the striking resemblance between the chronic diarrhea, wasting, and mucosal appearance in cattle JD and human CD, and the search for a mycobacterial cause of CD began. Numerous anti-TB drug trials were undertaken however the results showed a disappointing lack of efficacy, 39 leading scientists away from an infective cause and toward the "autoimmunity" hypothesis-a popular concept at the time. We now know the older anti-TB drugs employed were largely ineffective against MAP. 40 It was only with the availability of novel intracellularly active macrolides to combat Mycobacterium avium Complex in acquired immune deficiency syndrome that significant reductions in CD severity, with profound healing of severe inflammation, 41, 42 complete mucosal healing, and scarring were achieved. 41 
CONTENTIOUS ISSUES
Despite satisfying both Koch's and Relman's causality Postulates, 25, 26, 29 some contentious issues remain. To date, no comprehensive review has been published to counter published arguments against MAP causality in CD. These issues are addressed below. Because of MAP's extremely slow growth, intracellular location, negative Ziehl Neelsen staining, and lack of detection using light microscopy, it has been extremely difficult to identify MAP in CD tissues until recently. However, technological advancements, particularly polymerase chain reaction, have allowed MAP DNA identification in up to 92% of CD tissues versus 26% of controls. 43 Another study examining resected bowel tissue in 300 subjects identified MAP DNA in 52% of CD patients versus only 2% of ulcerative colitis (UC) patients and 5% of controls. 44 A further study identified MAP DNA in 6/7 (86%) resected CD tissue versus 2/36 (5.6%) in control specimens. 45 Incidentally, the much lower prevalence of MAP in UC tissue versus CD discounts the notion that MAP is a mere bystander organism which "innocently lodges in ulcerated mucosa." 1 The presence of MAP, a known pathogen in diseased human tissue in individuals with CD suggests that until MAP zoonosis is disproven, its presence must be treated as pathogenic. The lack of MAP dissemination during immunosuppressive therapy has baffled CD experts, with 1 expert stating "the strongest negative evidence" of a" mycobacterial etiology" is the lack of exacerbating disease during immunosuppressive therapy. 5 We must first emphasize that this has no bearing on Koch's Postulates and causality. Numerous studies have confirmed the presence of MAP in CD tissues without a single recorded case of dissemination in the presence of concomitant immunosuppression. 7, 43, 46 The above author suggests that as immunosuppressive therapies reproducibly potentiate and disseminate TB infection 5 leading to miliary TB, 47 other members of the Mycobacterium family such as MAP should also disseminate.
To address these issues 2 fundamental points need to be considered:
M. tuberculosis is a unique pathogen, even among mycobacteria, in that it is adapted to replicate both in the vacuole and cytosol allowing the pathogen to escape from the phagosome to produce disseminated disease. 48 To understand the nondissemination of MAP, one must look to the "traditional mycobacterial infection"-leprosy, caused by Mycobacterium leprae, a pathogen that does not disseminate despite known treatment with azathioprine, steroids and TNF-a inhibitors. 49 The intracellular obligatory spheroplast form of MAP is incapable of replicating in the extracellular environment 50 and is therefore incapable of disseminated disease. In addition, commonly used anti-inflammatory and immunosuppressive agents (eg, 5-aminosalicylic acid, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus) inhibit MAP activity. 51, 52 Mendoza et al, 7 despite detecting MAP DNA in the blood of 100% (30/30) of CD patients, did not report any incidence of MAP dissemination in those 14 of 30 patients (46.6%) who had concomitant infliximab and immunosuppressant use. Anti-TNF-a antibodies have additionally been shown to induce apoptosis of TNF receptor-positive lymphocytes and macrophages. 53, 54 Naser et al 46 This argument was made several years ago and has since been disproven by work performed in several laboratories. Olsen et al 56 isolated MAP-reactive CD4 T cells from the mucosa of CD patients convincingly disproving this argument. Several other groups have since demonstrated MAP-specific T-cell responses in CD patients. [57] [58] [59] [60] A positive association between MAP T-cell response and CD was obtained when MAP-activated peripheral blood lymphocytes from CD patients showed an increased suppression of a mitogen-stimulated lymphoproliferative response in an antigen-specific manner. 61 Gut mucosal inflammation involves either Th1, Th2, or Th17 cytokine patterns with an excessive Th1/Th17 response believed to drive CD disease activity. However, a recent study reported a diminished MAP-specific Th1 response as determined by an interferon-g response in MAP-positive CD patients when compared with MAP-positive control subjects. 58 Using a whole blood culture system to determine the relationship between T-cell responses and MAP in CD patients revealed interleukin (IL)-2 and IL-4 levels in plasma supernatants that were significantly higher in MAP-positive patients compared with MAP-negative patients, normal controls, and UC patients. 59 The findings of a selective Th2 cytokine response to MAP was supported by in-vitro MAP stimulation of peripheral blood mononuclear cells (PBMNCs) from CD patients that produced higher levels of Th2 cytokines than those produced in cultures stimulated with Salmonella typhimurium (S. typhimurium). 60 In addition, Th1/Th2 cytokine ratios were lower for CD patients than those observed for healthy control subjects when PBMNC were stimulated with MAP but not S. typhimurium. The skewed MAP-specific Th2 response in CD patients is consistent with that observed in cultures of chronically MAPinfected goat and cattle PBMNCs stimulated with MAP antigen in vitro under the influence of regulatory T cells 61, 62 and favors intracellular MAP survival in macrophages.
Issue 4: No Evidence of Transmission of Disease by Epidemiological Studies 2,5
The rising IBD incidence worldwide cannot be accounted for by a genetic immune system dysregulation, incapable of altering over a few decades. 33 Some contend that if MAP were the cause, a higher CD incidence in veterinarians and farmers exposed to MAP-infected animals would occur. Yet US data suggests that these occupations protect against IBD. 63 In addition, children exposed to farm animals, particularly cattle, in early life have a lower CD incidence. 64 Raised antibodies to MAP lysates have been detected in adults with occupational exposure to MAP. 65 Hermon-Taylor 66 has contended that exposure to the extracellular Ziehl Neelsen-positive MAP phenotype excreted by shedding animals is not the human-susceptible form. MAP passaging through bovine macrophages in milk and cheese, and various protists in wet environmental locations have been hypothesized as completing the transformation. 67, 68 In contrast, continual exposure to animal environmental MAP likely results in partial immunity against the human-susceptible MAP, 65 akin to the subclinical infection seen in hepatitis B where long-term exposure results in the development of protective immunity. 69 Chronic low-dose H. pylori exposure induces a similar immunity, with Radcliff and Ferrero 70 reporting significantly lower H. pylori bacterial loads in mice preexposed to a subinfectious dose.
However, a progressive increase in CD prevalence has been reported in MAP-endemic areas. In Iceland, JD incidence increased from 0% to 30% over an 18-year period after introduction of MAP-infected sheep into the local sheep population in 1938. 71 A subsequent study reported increased IBD incidence in Iceland occurring over a combined period of 40 years (1950 to 1989). 72 In another study the mean CD incidence was seen to rise from 0.5 to 5.5/100,000 between 1950 and 1994, a 10-fold increase. 73 With MAP the slowest known growing bacterial species it would seem that epidemiological studies spanning 40 to 50 years are required to show MAP trends. In a Sardinian island community where JD and MAP infection are widespread in cattle and sheep, 83.3% with CD and 10.3% control subjects tested positive for MAP DNA, consistent with widespread human exposure from contaminated dairy supplies and the environment. 74 Of these, MAP was successfully cultured from 63.3% CD subjects and 10% of control subjects. Another study in an Indian rural community in Agra District, north India, reported that 5 of 5 (100%) CD subjects; 6 of 8 (75%) goat herders working with JD-affected goats versus 27 of 71 (38%) normal controls tested positive for MAP by polymerase chain reaction, culture, and enzyme-linked immunosorbent assay. 75 The MAP isolates from patients had a "bison" genotype indigenous to the region and was shared between wildlife antelopes and livestock (goats and sheep) through interspecies transmission. 76 Multiple reports of CD clustering among unrelated individuals, family members, and close friends have been reported in the literature. [77] [78] [79] [80] [81] [82] [83] [84] One study of graduates from the Mankato West High School was conducted after reports of CD clustering in students. 82 Seven CD cases of 285 students were documented and 2 additional students reported symptoms of CD. Bearing in mind CD incidence in the general population is approximately 7 per 100,000 cases, this is a remarkable prevalence of 2456 per 100,000 cases, a 350-fold increase. One of the richest agricultural regions in the nation, producing abundant cattle, swine, corn, and soybeans, the river flows through Mankato delivering surface water from a wide fan-shaped watershed to the south. Fecal coliform counts of the river are in excess of 200/dL year after year, regarded as unsafe for recreational use. All the 7 CD students reported prior recreational swimming in the lakes. In a more recent study, Pierce et al 83 reported an IBD outbreak in 15 unrelated children and teenagers living in close proximity to dairy farms in Forest, Virginia. Two of the children lived immediately adjacent to dairy farms and the others were close to Ivy Lake, Otter River, Elk Creek, and Ivy Creek and their tributaries, all of which receive water runoff from 4 of the 6 farms currently located in Forest. Five of the 7 CD samples tested strongly positive for MAP antibodies.
Similarly the statement that "no evidence of increased frequency of Crohn's Disease in parents and offspring" 1 is false. Van Kruiningen et al 84 reported a French family whose 6 members developed CD, including a daughter-inlaw. The son first developed CD in 1974 before meeting his wife, whom he married in 1983. After the marriage she then went on to develop CD in 1991. Another study reported CD clustering among 3 unrelated, unmarried men who shared a sustained friendship and who, all within a decade of their initial contact, developed IBD. 85 Issue 5: "Antibiotic Studies do not Show any Long-Lasting Benefit" 5 To understand the difficulty in treating MAP we must look to anti-MAP therapy in the treatment of JD in cattle of considerable genetic worth. St Jean, conducting the most comprehensive review of anti-MAP in JD, concluded that "therapy for clinical paratuberculosisyrequires daily medication for long periods and does not provide a definitive cure, only achieving remission and palliation of the disease." 31 As in Mycobacterium avium Complex infection anti-MAP therapy should be employed for 1 year or longer and comprise a multidrug regimen with intracellularly active antibiotics. 86 Numerous published drug studies examining the use of multidrug regimens containing macrolides in CD have shown long-term benefits. 87, 28, 41, 42 The largest of these was a randomized controlled trial of triple antibiotic therapy (clarithromycin, rifabutin, clofazimine). 28 Despite the major study design faults, deficient drug dosing, drug delivery failure, and incorrect results analysis [87] [88] [89] [90] the trial demonstrated a 66% remission rate in CD at 16 weeks versus 50% in placebo with no further benefit beyond this time point. However, using the statistically appropriate intention-to-treat reanalysis, it was found that the benefit at 16 weeks persisted at 52 and 104 weeks, with significant differences between anti-MAP therapy and placebo at these time points, 91 demonstrating long-lasting benefit. The results observed in this controlled trial are consistent with those reported in earlier open-label studies. Gui et al 87 reported 52 patients treated with a therapy containing macrolides for periods of 6 to 35 months (mean 18.7 mo). A reduction in inflammation scores were observed in 49 of 52 (89%) patients with only 2 of 19 steroid-dependent patients remaining on steroids. A sustained clinical improvement in 21 of 29 patients (72%) who tolerated triple antibiotic therapy was achieved in a follow-up study for 4 to 17 months. 92 Another study using triple antibiotic therapy containing macrolides over a period of 52 to 54 months in 12 CD patients achieved complete clinical, endoscopic, and histologic remission in 6 of 12 patients (50%) for up to 10 years. 93 In an open-label retrospective study, 52 patients with active CD were followed up for 6 months to 9 years. 94 The triple antibiotic therapy achieved clinical, colonoscopic, and histologic remission in 32 of these patients (61.5%). In addition, 22 of 39 patients (56.4%) who achieved complete clinical remission exhibited mucosal healing. 41 Given the poor response of MAP treatment in JD, the results of these trials are surprisingly good and certainly remain a far more effective therapy with fewer side effects than published results for the widely marketed infliximab in CD. [95] [96] [97] [98] Issue 6: "Abundant Clinical Evidence Implicates the Commensal Enteric Flora in the Pathogenesis of CD" 5 The "abundant clinical evidence" implicating the commensal enteric flora in CD pathogenesis comes from the results of several uncontrolled studies of diminutive sample size. [99] [100] [101] That being said, the enteric flora clearly plays a role as a potential reservoir of chronic infection. Normal uninfected flora causes no mucosal inflammation and can be used therapeutically to cure Clostridium difficile (C. difficile) colitis [102] [103] [104] [105] [106] [107] [108] [109] and idiopathic colitis. [110] [111] [112] In contrast, flora infected with Salmonella, Shigella, Campylobacter, C. difficile, and other pathogens induces enteric/mucosal inflammation until the pathogen is eradicated. There is currently no abundant clinical evidence which implicates the commensal flora in the pathogenesis of CD. Indeed the evidence implicates infected commensal flora. This is quite clear given the following. 1. Rutgeerts et al 100 himself indicated that a "factor" in the fecal stream was the culprit. 2. He demonstrated that when the fecal was restored, the "factor" reinitiated the CD. 100 However a "commensal" flora control group, that is an infusion of commensal flora from an unrelated individual without CD into CD patients, was not used to show that commensal flora can restart CD. However, this is known not to be the case, 110 as healthy commensal flora successfully reverses UC inflammation and 1 case of CD, likely by recolonization as in C. difficile colitis. 110 3. Given the lack of a control group in D'Haens and colleagues study, histologic inflammation due to repeated Foley catheter trauma may well be the published finding. 99, 113 
CONCLUSIONS
The "aberrant mucosal reaction" versus "MAP" debate is likely to continue among opinion leaders. Several published "issues" have divided the medical community and this review counters these widely held and often inaccurate beliefs. The causality debate is by no means trivial and carries important consequences for patients and physicians seeking evidence-based rationale to treat often desperate, nonresponsive CD patients. The peril is that we become so enamored with discovering the role of the multitude of microbes and cytokines and their influence on immune pathways that we disregard the basic infectious disease tenets and attribute CD to commensal bacteria while some patients continue to harbor a proven and untreated pathogen.
It is time for us who previously could not "see," to become that Da Vinci group that has been shown the evidence and now can "see."
